Related Experiment Videos
Crkl enhances leukemogenesis in BCR/ABL P190 transgenic mice
B Hemmeryckx1, A van Wijk, A Reichert
1Department of Hematology/Oncology, Childrens Hospital Los Angeles Research Institute and the Keck School of Medicine of the University of Southern California, 90027, USA.
Cancer Research
|March 14, 2001
Summary
Crkl protein overexpression accelerates tumor development and leukemia in mice. This adapter protein plays a key role in tumorigenesis and Bcr/Abl-driven leukemogenesis.
Area of Science:
- Molecular Biology
- Oncology
- Cell Biology
Background:
- Crkl adapter protein is linked to abnormal signaling in Bcr/Abl oncoprotein-driven Philadelphia-positive leukemias.
- Investigating Crkl's role in tumorigenesis is crucial for understanding cancer development.
Purpose of the Study:
- To determine the role of Crkl in tumorigenesis and leukemogenesis using a transgenic mouse model.
- To analyze the impact of Crkl overexpression on cellular signaling and tumor formation.
Main Methods:
- Generated transgenic mice expressing human Crkl under the CRKL promoter.
- Utilized Western blot analysis to confirm Crkl overexpression and complex formation with C3G.
- Assessed integrin-based macrophage motility and tumor incidence in transgenic mice.
- Coexpressed Crkl and Bcr/Abl in mice to evaluate effects on leukemia development.
Main Results:
- Transgenic mice showed 4-6 fold overexpression of Crkl, leading to increased Crkl-C3G complex formation.
- Crkl overexpression significantly enhanced integrin-based macrophage motility.
- Tumor incidence increased in Crkl-overexpressing mice, with Rap1 activation observed in metastatic mammary carcinoma.
- Coexpression of Crkl and Bcr/Abl accelerated leukemia/lymphoma development, reducing survival by 3.8 months.
Conclusions:
- Crkl plays a direct role in tumor development and progression.
- Crkl is critical in the leukemogenesis process mediated by Bcr/Abl.
- Targeting Crkl may offer therapeutic strategies for Bcr/Abl-positive leukemias and other cancers.